1. Introduction

Commercial epigenetic services represent an emerging area of biotechnology involving the study, measurement and modification of gene expression without changing the underlying DNA sequence. These services use scientific techniques to examine how environmental, nutritional, chemical, behavioural and biological factors influence gene activity.

Examples include:

Epigenetic testing and DNA methylation profiling.

Biological-age and epigenetic-age testing.

Histone modification analysis.

Epigenetic biomarker identification.

Commercial laboratory research and testing.

Personalised wellness and preventive-health reports.

Epigenetic drug-development and pharmaceutical research.

Commercial licensing of epigenetic technologies and databases.

The taxation of these services raises complex questions concerning the classification of biotechnology services, GST, income tax, research expenditure, intellectual property, royalties, cross-border transactions and the treatment of genetic and epigenetic data.

The central legal issue is whether a commercial epigenetic service should be treated as a healthcare service, diagnostic laboratory service, scientific research service, information technology service, consultancy service or intellectual-property transaction.

The answer depends on the actual nature of the activity, contractual arrangements and applicable tax legislation.

2. Meaning and Scope of Commercial Epigenetic Services

Epigenetic services generally involve analysing biological markers that influence gene expression.

For taxation purposes, they can be divided into six categories:

Each category may attract a different tax treatment.

For example, a laboratory charging a pharmaceutical company for contract epigenetic research may be treated differently from a recognised healthcare provider supplying exempt clinical healthcare services.

3. GST Treatment of Commercial Epigenetic Services in India

The principal legislation is the Central Goods and Services Tax Act, 2017, together with the applicable GST rate and exemption notifications.

There is no separate GST category specifically named commercial epigenetic services. Consequently, classification depends on the actual supply.

A. Healthcare and diagnostic services

Entry 74 of Notification No. 12/2017–Central Tax (Rate), dated 28 June 2017, provides an exemption for specified healthcare services supplied by a clinical establishment, authorised medical practitioner or para-medics.

The definition of a clinical establishment includes establishments providing diagnostic or investigative services through laboratory or medical equipment.

Therefore, epigenetic testing may qualify for exemption where:

The supplier satisfies the definition of a clinical establishment.

The activity constitutes healthcare services.

The service is genuinely diagnostic or investigative in a healthcare context.

The other statutory conditions for exemption are satisfied.

Examples may include clinically indicated DNA methylation tests conducted to assist a qualified medical practitioner in diagnosis or treatment.

B. Commercial wellness and lifestyle testing

A different position may arise where a company sells epigenetic-age testing, lifestyle reports or biological-age assessments directly to consumers.

For example:

Biological-age estimation for fitness purposes.

Personalised longevity reports.

Lifestyle optimisation recommendations.

Consumer epigenetic profiling without clinical diagnosis.

These activities should not automatically be treated as exempt healthcare services.

If the supplier does not meet the conditions of the healthcare exemption, the service will ordinarily be taxable under the applicable GST classification and rate.

C. Contract research and laboratory services

Where a biotechnology company undertakes epigenetic research for pharmaceutical companies, universities or research institutions, the transaction may be classified as scientific or technical testing, analysis or research services.

The following distinction is important:

The actual GST rate must be determined from the applicable tariff classification and notifications rather than assuming that all biotechnology services carry the same rate.

4. Important GST Judicial Decisions

1. Matrix Imaging Solutions – Karnataka Authority for Advance Ruling, 30 September 2019

The authority considered whether diagnostic services supplied to hospitals and other establishments qualified for exemption under Entry 74 of Notification No. 12/2017.

It concluded that the diagnostic services in question were covered by the healthcare-service exemption.

Relevance: Commercial epigenetic laboratories may rely on the reasoning where their activities constitute qualifying diagnostic services supplied by a clinical establishment. However, the ruling does not automatically exempt every independent biotechnology laboratory.

GST Karnataka

2. Soham Healthcare Pvt. Ltd. – Gujarat Authority for Advance Ruling, 2020

The ruling examined the definition of clinical establishment, including establishments carrying out genetic, biological, chemical and other diagnostic investigations using laboratory equipment.

Relevance: Genetic and biological investigations are expressly relevant to the statutory definition. Epigenetic testing may fall within the same conceptual framework where the remaining healthcare-exemption requirements are met.

Goods & Services Tax Council

3. Ernakulam Medical Centre Pvt. Ltd. – Kerala Advance Ruling, 2018

The advance-ruling proceedings considered healthcare services and ancillary supplies provided to inpatients.

The reasoning recognised that where healthcare is the principal supply, ancillary goods and services forming part of the composite supply may follow the exemption applicable to healthcare.

Relevance: Where epigenetic diagnostic testing forms an integral part of qualifying patient healthcare, its tax treatment may depend on the principal supply and the composite-supply provisions.

Goods & Services Tax Council

Legal qualification: Advance rulings generally bind the applicant and the concerned jurisdictional officers under the statutory framework; they are not equivalent to binding Supreme Court precedents.

5. Income Tax Treatment of Epigenetic Businesses

Commercial epigenetic companies may earn income from:

Laboratory testing fees.

Scientific research contracts.

Epigenetic software subscriptions.

Licensing of testing methods.

Sale of diagnostic kits.

Pharmaceutical research agreements.

Intellectual-property royalties.

Such receipts generally fall within the applicable business-income provisions, depending on the nature of the business and transaction.

For transactions from 1 April 2026, the principal legislation is the Income-tax Act, 2025.

A. Section 45 – Expenditure on scientific research

Section 45 is particularly important for biotechnology companies.

It provides deductions for qualifying scientific research expenditure, subject to the statutory requirements.

Relevant expenditure may include:

Research scientists' salaries.

Laboratory consumables.

Experimental equipment.

Research-related operating costs.

Qualifying capital expenditure.

Research expenditure incurred before commencement of business, where statutory conditions are fulfilled.

Section 45(2) specifically addresses qualifying in-house scientific research and development facilities of biotechnology companies.

However, a company cannot claim that every commercial laboratory expense is scientific research expenditure.

Important distinction:

The Income-tax Rules, 2026, Rule 29 prescribes the approval process and conditions for qualifying in-house R&D facilities.

IndiaCode+1

6. Important Income Tax Case Laws

1. CIT v. Claris Lifesciences Ltd. (2008), 326 ITR 251 (Gujarat High Court)

The dispute concerned deduction for expenditure on an approved in-house research and development facility under Section 35(2AB) of the Income-tax Act, 1961.

The High Court interpreted the provision in a manner that recognised qualifying expenditure incurred in developing the facility, rather than treating the approval date as an automatic cut-off.

Legal principle: Genuine research and development expenditure should be evaluated according to the statutory conditions and the nature of the research facility.

Epigenetic relevance: A biotechnology company developing a new epigenetic biomarker platform may rely on this principle when establishing its research expenditure entitlement.

CourtKutchehry+1

2. CIT v. Sandan Vikas (India) Ltd. (2011), 335 ITR 117 (Delhi High Court)

The case concerned the eligibility of research expenditure under Section 35(2AB), including the timing of approval of the in-house R&D facility.

The Delhi High Court considered the approach adopted in Claris Lifesciences and recognised that the statutory requirements, rather than an unnecessarily restrictive interpretation of the approval date, must govern eligibility.

Legal principle: The existence of genuine research activity and compliance with statutory approval requirements are important in determining deductions.

Epigenetic relevance: Companies undertaking genuine methylation research, epigenetic drug discovery and biomarker development can use this decision as an interpretative precedent.

taxindiaonline.com+1

3. Biocon Ltd. v. DCIT, Karnataka High Court, 12 January 2021

The dispute involved the interaction between research-related deductions under Section 35(2AB) and export-related deductions.

The High Court recognised that the respective statutory deductions operate independently, provided the conditions of each provision are independently satisfied.

Legal principle: Eligibility for one tax deduction does not automatically defeat another independent statutory tax benefit.

Epigenetic relevance: An Indian biotechnology company exporting epigenetic testing technology or research services may examine its research deduction and export-related tax treatment separately, subject to the applicable provisions and current tax regime.

IndiaCode

4. Banco Products (India) Ltd. v. DCIT, Gujarat High Court, 26 March 2018

The dispute concerned the timing of approval for an in-house research facility and eligibility for Section 35(2AB) benefits.

The court considered whether expenditure incurred during the relevant period could be denied merely because of the way the approval period was expressed.

Legal principle: The statutory purpose of encouraging genuine research and development must inform the interpretation of the approval requirements.

Epigenetic relevance: This decision is useful when a biotechnology enterprise has incurred substantial expenditure while establishing its epigenetic research facility.

IndiaCode+1

Note: These judgments interpret the former Income-tax Act, 1961. Their principles remain relevant to corresponding provisions of the Income-tax Act, 2025, but the new statutory language and rules must independently be satisfied.

7. Taxation of Epigenetic Intellectual Property

Epigenetic commercial enterprises frequently develop valuable intellectual property.

Examples include:

DNA methylation algorithms.

Epigenetic biomarker databases.

Proprietary laboratory methods.

Histone-modification analysis techniques.

Epigenetic diagnostic software.

Patented biotechnology processes.

The taxation depends on whether the company sells the intellectual property outright or merely permits another business to use it.

A. Intellectual-property licensing

When an Indian company licenses proprietary epigenetic technology to another business, the income may constitute royalty or business income depending on the contractual rights transferred.

For international transactions, the definition of royalty under Section 9 of the Income-tax Act, 1961, and the corresponding provisions of the Income-tax Act, 2025, must be examined.

B. Transfer of intellectual property

An outright transfer of qualifying intellectual-property rights may have capital-gains consequences.

The legal distinction between a transfer of ownership and a limited right to use technology is important.

C. Software and algorithm licensing

Epigenetic software subscriptions, cloud-based analysis tools and algorithm-access agreements require careful classification.

The agreement must distinguish between:

Access to a software platform.

Transfer of copyrighted rights.

Technical consultancy.

Scientific research services.

Licensing of proprietary technology.

A mere software subscription does not automatically constitute a royalty payment.

8. International Taxation of Commercial Epigenetic Services

Epigenetic services increasingly involve international transactions.

For example, an Indian biotechnology company may:

Collect biological samples in India.

Send samples to a laboratory in Singapore.

Receive epigenetic test results.

Licence its analysis software to a US pharmaceutical company.

Sell research reports to European healthcare institutions.

These transactions may raise several tax issues.

A. Double taxation agreements

Where an Indian company receives foreign income or pays overseas laboratories, the relevant double taxation avoidance agreement (DTAA) may determine the taxing rights of the countries involved.

B. Transfer pricing

Transactions between associated enterprises involving epigenetic research, intellectual property and laboratory services must comply with the applicable transfer-pricing provisions.

The following require particular attention:

Research and development cost allocation.

Royalty payments.

Licensing of proprietary algorithms.

Contract research pricing.

Transfer of valuable intangible assets.

Allocation of risks relating to unsuccessful research.

C. GST on exports

Where epigenetic research or laboratory services are supplied to overseas customers, the export-of-services conditions under Section 2(6) of the IGST Act, 2017, must be satisfied.

Qualifying exports are treated as zero-rated supplies under Section 16 of the IGST Act, subject to applicable procedures and restrictions.

However, a foreign customer alone does not automatically establish an export of services.

9. Input Tax Credit and GST Compliance

Commercial epigenetic laboratories often purchase expensive scientific equipment and consumables.

Examples include:

DNA methylation analysis instruments.

PCR equipment.

Sequencing-related equipment.

Laboratory chemicals.

Reagents.

Research software.

Cloud computing services.

Under Sections 16 and 17 of the CGST Act, eligible input tax credit may be available when statutory requirements are satisfied.

However, where a laboratory supplies exempt healthcare services and taxable commercial services, input tax credit must be apportioned according to the applicable provisions.

This is particularly important for laboratories operating both clinical diagnostic and commercial research divisions.

Example:

An epigenetic laboratory provides:

Exempt qualifying clinical diagnostic services.

Taxable commercial biological-age testing.

Taxable contract research.

The laboratory must maintain proper accounting records and determine the credit attributable to taxable and exempt supplies.

It cannot automatically claim the entire GST paid on common laboratory expenses.

10. Taxation of Different Commercial Epigenetic Business Models

11. Major Legal Challenges in Epigenetic Taxation

Commercial epigenetic services create several unresolved or developing taxation questions.

1. Classification uncertainty: Whether biological-age testing is healthcare, scientific investigation or commercial wellness activity.

2. Research versus commercial testing: Distinguishing experimental scientific research from routine laboratory operations.

3. Intellectual-property valuation: Determining the appropriate value of proprietary methylation algorithms and epigenetic databases.

4. Cross-border taxation: Determining whether payments are royalties, technical-service fees or ordinary business receipts.

5. Research incentives: Establishing whether a commercial epigenetic company satisfies the statutory conditions for research deductions.

6. Taxation of biological data: Determining the tax treatment of commercial arrangements involving the licensing, analysis and commercial exploitation of epigenetic datasets.

7. Composite supplies: Determining whether laboratory testing, medical consultation and reporting constitute independent supplies or a composite healthcare service.

12. Suggestions for Tax Regulatory Reform

India could consider developing a more specialised tax framework for emerging epigenetic businesses.

Possible reforms include:

Clear GST classification guidelines for epigenetic diagnostic services.

Specific guidance on commercial biological-age testing.

Transparent R&D certification procedures for epigenetic laboratories.

Clear rules for valuation of biotechnology intellectual property.

Tax incentives for genuine epigenetic research.

International standards for transfer pricing of genomic and epigenomic technologies.

Clear distinctions between clinical testing, scientific research and wellness services.

Appropriate tax treatment for commercialisation of biotechnology databases.

13. Conclusion

Taxation of commercial epigenetic services represents an important emerging intersection between biotechnology, healthcare, intellectual-property law and fiscal regulation.

In India, the applicable tax treatment primarily depends on the nature of the service, the legal status of the supplier, the contractual arrangements and the relevant statutory exemptions.

The Income-tax Act, 2025, particularly Section 45, provides an important framework for qualifying scientific research expenditure. GST legislation provides potential healthcare exemptions for qualifying diagnostic establishments, while commercial wellness services, research contracts and intellectual-property licensing generally require separate classification.

The decisions in Claris Lifesciences, Sandan Vikas, Biocon and Banco Products provide useful interpretative principles concerning scientific research deductions. The GST advance rulings concerning Matrix Imaging Solutions and Soham Healthcare provide additional guidance on diagnostic-service classification.

The ultimate legal principle is that taxation should follow the actual substance of an epigenetic transaction rather than merely the scientific terminology used by the business.

14. Important Statutory and Judicial References

For statutory verification, consult the Income-tax Act, 2025 and the Karnataka diagnostic-services advance ruling.

Research qualification: There is no established reported Indian Supreme Court judgment specifically deciding the taxation of commercial epigenetic services. The cases discussed above are analogous authorities, not direct epigenetics precedents. The GST advance rulings also have limited statutory binding effect.